BLAINJECTIONINJECTABLEPriority Review
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
7/8 — Comprehensive
Priority Review
ENTYVIO (vedolizumab) by Takeda is integrin receptor antagonists [moa]. Approved for ulcerative colitis, crohn's disease, inflammatory bowel disease. First approved in 2014.
ENTYVIO (vedolizumab) is a monoclonal antibody integrin receptor antagonist approved by the FDA on May 20, 2014, administered via injection. It selectively blocks α4β7 integrin on immune cells, reducing their migration to the gastrointestinal tract to treat inflammatory bowel diseases. The product represents a targeted immunosuppressive approach for patients with ulcerative colitis and Crohn's disease who have inadequate response to conventional therapies or biologics.
$0.1BPart D
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Indications (3)
Worked on ENTYVIO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.